Price Disclosure. Any price mentions except as permitted by Licensee's policies current at the time.
Price Disclosure. Any price mentions except as permitted by Programmer's policies current at the time.
Price Disclosure. The price as- signed to this instrument may have been provided by a national pricing service and is derived from a “market-driven pricing model.” This price may not be the actual price you would receive in the event of a sale prior to the maturity of the CD. Additional information is available upon request.
Price Disclosure. Any price mentions exceppt as permitted by Programmer's policies current at the time.
Price Disclosure. Any price mentions except as permitted by Licensees' policies current at the time.
Price Disclosure. Upon request by the University, the ESCO shall be required to fully disclose all costs and fees associated with this project, and shall follow industry standards for open book pricing, including audit, design, engineering, equipment, installation, financing, commissioning, monitoring, overhead, profit, etc.
Price Disclosure. Any price mentions except as permitted by applicable law.
Price Disclosure. Any price mentions except as permitted by Owner’s policies current at the time.
Price Disclosure. Over time, medicines listed on F2 will move to a system of price disclosure where the price that the Government pays will reflect more closely the actual price at which the medicine is being supplied to wholesalers and pharmacists. A transitional pricing arrangement will apply to F2 with two sub-formularies being created: • Formulary 2A (F2A) will comprise medicines that did not attract significant trading terms to pharmacy at 1 October 2006 (i.e. less than 25%). • Formulary 2T (F2T) will comprise medicines that did attract significant trading terms to pharmacy at 1 October 2006 (i.e. 25% or more), and other medicines interchangeable with them at the patient level.
